BIOGEN INC. — fact timeline

BIOGEN INC. shareholders approved Advisory vote on executive compensation at the 2026-06-09 meeting.

“Stockholders approved the advisory vote on executive compensation”

BIOGEN INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-09 meeting.

“Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026”

BIOGEN INC. shareholders approved Election of Directors at the 2026-06-09 meeting.

“Stockholders elected ten nominees to the Board of Directors to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified”

BIOGEN INC. entered into Credit Agreement with U.S. Bank National Association valued at The Credit Agreement provides for unsecured term loan facilities in an aggregate principal amount of (effective 2026-05-12).

“On May 12, 2026, Biogen entered into a Credit Agreement with U.S. Bank National Association (“U.S. Bank”), as administrative agent, and the lenders party thereto (the “Credit Agreement”).”

BIOGEN INC. entered into Contingent Value Rights Agreement with Apellis Pharmaceuticals, Inc. valued at Each CVR represents a non-transferable contractual contingent right to receive the following cash pa (effective 2026-05-14).

“on May 14, 2026, Biogen, Apellis and Equiniti Trust Company, LLC, a New York limited liability trust company, entered into a Contingent Value Rights Agreement (the “CVR Agreement”) governing the terms of the CVRs (as defined below) issued pursuant to the Offer and the Merger (as defined below).”

BIOGEN INC. incurred term loan of $1 billion with U.S. Bank National Association at Term SOFR plus an applicable margin ranging from 0.750% to 1.000% maturing May 12, 2028.

“The Credit Agreement provides for unsecured term loan facilities in an aggregate principal amount of $2 billion (the “Term Facilities”), comprised of a $1 billion 364-day tranche (“Tranche A”) and a $1 billion two-year tranche (“Tranche B”).”

BIOGEN INC. incurred term loan of $1 billion with U.S. Bank National Association at Term SOFR plus an applicable margin of 0.750% or Base Rate plus an applicable ma maturing May 12, 2027.

“The Credit Agreement provides for unsecured term loan facilities in an aggregate principal amount of $2 billion (the “Term Facilities”), comprised of a $1 billion 364-day tranche (“Tranche A”) and a $1 billion two-year tranche (“Tranche B”).”

BIOGEN INC. completed an acquisition involving Apellis Pharmaceuticals, Inc. for Cash Amount of $41.00 per Share plus one CVR per Share representing contingent cash payments of up to an aggregate of $4.00 per Share (closed 2026-05-14).

“CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”).”

BIOGEN INC. reported the first quarter ended March 31, 2026 results: revenue $2,478, EPS GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57. Guidance raised.

“and reported important positive new data that reinforce our confidence in the late‐stage pipeline." Financial Highlights Q1 '26 Q1 '25 △ r (CC * ) Total Revenue (in millions) $2,478 $2,431 2% (2)% GAAP diluted EPS $2.15 $1.64 31% N/A Non-GAAP diluted EPS $3.57 $3.02 18% N/A Note: Percent changes represented as favorable/(unfavorable) versus the prior year”

BIOGEN INC. reported preliminary financial results for the first quarter of 2026.

“Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis.”

BIOGEN INC. entered into Merger Agreement with Apellis Pharmaceuticals, Inc. valued at $41.00 per share of Apellis Common Stock (effective 2026-03-31).

“On March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”).”

Michael McDonnell departed as Chief Financial Officer at BIOGEN INC..

“Mr. McDonnell will retire on March 1, 2025.”

Robin Kramer was appointed as Chief Financial Officer at BIOGEN INC..

“As previously announced, Ms. Kramer has been appointed the Company’s Chief Financial Officer, effective upon the retirement of Michael McDonnell, the Company’s current Chief Financial Officer.”

Sean Godbout was appointed as Chief Accounting Officer at BIOGEN INC..

“On January 13, 2025, Biogen Inc. (the “Company”) appointed Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller and designated Mr. Godbout as the Company’s principal accounting officer, in each case effective as of March 1, 2025.”

Robin Kramer was appointed as Chief Financial Officer at BIOGEN INC..

“Robin Kramer, the Company’s Chief Accounting Officer and Head of Global Business Services and Treasury has been appointed Chief Financial Officer effective upon Mr. McDonnell’s retirement.”

Michael McDonnell departed as Chief Financial Officer at BIOGEN INC..

“On October 28, 2024, Michael McDonnell, Chief Financial Officer of Biogen Inc. (the “Company”) notified the Company that he will retire from the Company effective February 28, 2025.”

Sir Menelas (Mene) Pangalos was elected as director at BIOGEN INC..

“On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders.”

Lloyd B. Minor was elected as director at BIOGEN INC..

“On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders.”

BIOGEN INC. reported first quarter ended March 31, 2024 results: revenue $2.3 billion, EPS $2.70. Guidance reaffirmed.

“Biogen reports first quarter 2024 GAAP EPS growth of 1% and Non-GAAP EPS growth of 8% First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67 First quarter product revenue decreased 3% and total revenue decreased 7%, while GAAP operating income grew 10% and Non-GAAP operating income grew 24%; meaningful improvement in both gross and operating margins due to Fit for Growth program and R&D prioritization LEQEMBI launch uptake accelerated with first quarter global in-market sales of approximately $19 million, nearly triple the fourth quarter of 2023, and patients on therapy increasing nearly 2.5 times since the end of 2023. Significant increase in new patient starts observed in March which contributed over 20% of cumulative patients now on LEQEMBI. SKYCLARYS first quarter global revenue of $78 million with patient identification and access progressing in the U.S. and E.U. launch now successfully underway ZURZUVAE launch shows encouraging early trends SPINRAZ”

BIOGEN INC. reported full year 2024 results: revenue total revenue to decline by a low- to mid-single digit percentage vs. 2023, EPS Non-GAAP EPS of $15.00 to $16.00. Guidance initiated.

“Full year 2024 financial guidance: Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point • Expect total revenue to decline by a low- to mid-single digit percentage vs. 2023”

BIOGEN INC. reported full year 2023 results: revenue $9.8 billion, EPS GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72.

“Full year 2023 revenue $9.8 billion; GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72”

BIOGEN INC. reported fourth quarter 2023 results: revenue $2.4 billion, EPS GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95.

“Fourth quarter 2023 revenue $2.4 billion; GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95”

Monish Patolawala was elected as Director at BIOGEN INC..

“On November 6, 2023, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) elected Monish Patolawala as a director (term to expire at the 2024 Annual Meeting) to fill a vacancy, effective January 1, 2024.”

BIOGEN INC. reported third quarter ended September 30, 2023 results: revenue $2,530 million, EPS GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36.

“--- EX-99.1 (EX-99.1) --- Press Release Cambridge, Mass. – Nov. 8, 2023 Biogen reports third quarter 2023 results and updates full year 2023 guidance Third quarter revenue $2,530 million; GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 Poised for leadership in Alzheimer's disease with ongoing LEQEMBI launch and development of tau-directed ASO (BIIB080) • New”

BIOGEN INC. incurred term loan of $1.5 billion unsecured term loan facility with JPMorgan Chase Bank, N.A. at Term SOFR subject to a floor of 0.00% per annum plus an applicable margin rangin maturing Tranche A: 364 days after Funding Date; Tranche B: 3 years after Funding Date.

“On August 28, 2023, Biogen Inc. (the “ Company ”) entered into a Credit Agreement with JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as Administrative Agent, and the lenders party thereto (the “ Credit Agreement ”). The Credit Agreement provides for a $1.5 billion unsecured term loan facility, comprised of a $750 million 364-day tranche (“ Tranche A ”) and a $750 million three-year tranche (“ Tranche B ” and collectively, the “ Term Facility ”).”

BIOGEN INC. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as Administrative Agent, and the lenders party thereto valued at $1.5 billion unsecured term loan facility (effective 2023-08-28).

“On August 28, 2023, Biogen Inc. (the “ Company ”) entered into a Credit Agreement with JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as Administrative Agent, and the lenders party thereto (the “ Credit Agreement ”). The Credit Agreement provides for a $1.5 billion unsecured term loan facility”

BIOGEN INC.: Biogen Inc. amended its bylaws effective July 28, 2023 to (i) clarify that nominees for election or reelection must agree to adhere to Biogen's Code of Business Conduct and Corporate Governance Principles and (ii) remove the position of Vice Chair and add the position of Chair Pro Tem (effective 2023-07-28).

“Effective July 28, 2023, the Board of Directors of Biogen approved an amendment to Biogen's Fourth Amended and Restated Bylaws (the “ Fourth Amended and Restated Bylaws ”) to (i) clarify that nominees for election or reelection must agree to, among other things, adhere to Biogen’s Code of Business Conduct and Corporate Governance Principles and (ii) remove the position of Vice Chair and add the position of Chair Pro Tem.”

BIOGEN INC. entered into Agreement and Plan of Merger with Reata Pharmaceuticals, Inc. valued at $172.50 in cash (effective 2023-07-28).

“On July 28, 2023, Biogen Inc. (“ Biogen ”), River Acquisition, Inc. (“ Merger Sub ”), a Delaware corporation and a wholly-owned subsidiary of Biogen and Reata Pharmaceuticals, Inc. (“ Reata ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), pursuant to which, and upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into Reata (the “ Merger ”), with Reata surviving the Merger as a wholly-owned subsidiary of Biogen.”

BIOGEN INC. reported second quarter 2023 results: revenue $2,456 million, EPS $4.07. Guidance reaffirmed.

“Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S. Second quarter revenue $2,456 million; GAAP diluted EPS $4.07; Non-GAAP diluted EPS $4.02”

BIOGEN INC. shareholders approved Election of Susan K. Langer to the Board of Directors for a one-year term at the 2023-06-26 meeting.

“5. Stockholders elected Susan K. Langer to the Board of Directors to serve for a one-year term extending until the 2024 annual meeting of stockholders and her successor is duly elected and qualified, with the votes cast as follows: Votes For Votes Against Abstentions Broker Non-Votes 64,037,638 46,616,578 8,470,361 8,719,273”

BIOGEN INC. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-26 meeting.

“4. Stockholders approved, on an advisory basis, annually as the frequency of the advisory vote on executive compensation, with the votes cast as follows: 1 Year 2 Years 3 Years Abstentions 115,841,797 75,456 2,254,126 953,198”

BIOGEN INC. shareholders approved Advisory vote on executive compensation at the 2023-06-26 meeting.

“3. Stockholders approved the advisory vote on executive compensation, with the votes cast as follows: Votes For Votes Against Abstentions Broker Non-Votes 82,640,454 36,292,390 191,733 8,719,273”

BIOGEN INC. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-26 meeting.

“2. Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstentions Broker Non-Votes 123,393,644 4,311,034 139,172 —”

BIOGEN INC. shareholders approved Election of seven nominees to the Board of Directors for a one-year term at the 2023-06-26 meeting.

“1. Stockholders elected seven nominees to the Board of Directors to serve for a one-year term extending until the 2024 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows: Nominee Votes For Votes Against Abstentions Broker Non-Votes Caroline Dorsa 91,426,287 27,419,853 278,437 8,719,273 Maria C. Freire 75,764,531 43,230,969 129,077 8,719,273 William A. Hawkins 73,182,735 45,804,008 137,834 8,719,273 Jesus B. Mantas 92,085,202 26,910,381 128,994 8,719,273 Eric K. Rowinsky 68,024,971 50,987,191 112,415 8,719,273 Stephen A. Sherwin 93,133,091 25,889,684 101,802 8,719,273 Christopher A. Viehbacher 116,996,008 2,026,614 101,955 8,719,273”

BIOGEN INC. reported first quarter ended March 31, 2023 results: revenue $2,463 million, EPS $2.67. Guidance reaffirmed.

“three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance First quarter 2023 financial results • First quarter revenue $2,463 million; GAAP diluted EPS $2.67; Non-GAAP diluted EPS $3.40 Poised for leadership in Alzheimer’s disease (AD) with LEQEMBI and BIIB080 • LEQEMBI (lecanemab-irmb) FDA Accelerated”

BIOGEN INC.: Effective April 12, 2023, the Board approved amended bylaws to change the title of 'Chairman' to 'Chair' (effective 2023-04-12).

“Effective April 12, 2023, the Board of Directors of Biogen Inc. (the “Company”) approved the Company’s Fourth Amended and Restated Bylaws, as amended through April 12, 2023 (as so amended, the “Amended Bylaws”), to change the title of “Chairman” to “Chair.””

BIOGEN INC. reported full year 2023 results: EPS $15.00 to $16.00. Guidance initiated.

“Full Year 2023 Financial Guidance • Expect mid-single digit revenue decline versus 2022 and Non-GAAP EPS of $15.00 to $16.00”

BIOGEN INC. reported full year 2022 results: revenue $10,173 million, net income GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67, EPS GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67.

“Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67”

BIOGEN INC. reported the fourth quarter and year ended December 31, 2022 results: revenue $2,544 million, net income GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05, EPS GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05.

“growth drivers; Company reports full year 2022 results and provides full year 2023 guidance Full year 2022 revenue and Non-GAAP EPS exceed guidance • Fourth quarter revenue $2,544 million; GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05 • Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67 Positioned to lead in Alzheimer’s”

Michel Vounatsos departed as CEO at BIOGEN INC..

“Michel Vounatsos will step down as Biogen’s CEO and will resign from the Board.”

Christopher A. Viehbacher was appointed as Director at BIOGEN INC..

“Mr. Viehbacher will succeed Michel Vounatsos as director of Biogen effective November 14, 2022”

Christopher A. Viehbacher was appointed as President and CEO at BIOGEN INC..

“appointed Christopher A. Viehbacher, age 62, to serve as President and CEO of Biogen, beginning November 14, 2022.”

Chirfi Guindo departed as Executive Vice President for Global Product Strategy and Commercialization at BIOGEN INC..

“On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”).”

Michel Vounatsos departed as Chief Executive Officer at BIOGEN INC..

“Mr. Vounatsos will remain on the Board of Directors of Biogen until he steps down from his CEO position.”

Nancy L. Leaming departed as Director at BIOGEN INC..

“Pursuant to the retirement provisions set forth in the Company’s Corporate Governance Principles, Nancy L. Leaming will also retire from the Board effective as of the Company’s 2022 annual meeting of stockholders.”

Brian S. Posner departed as Director at BIOGEN INC..

“On January 25, 2022, Brian S. Posner notified Biogen Inc. (the “Company” or “Biogen”) that he will retire from the Biogen Board of Directors (the “Board”) effective as of the Company’s 2022 annual meeting of stockholders.”

Alfred W. Sandrock, Jr., M.D., Ph.D. departed as Head of Research & Development at BIOGEN INC..

“On November 15, 2021, Biogen Inc. (the “Company”) issued a press release announcing that Alfred W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company, effective December 31, 2021.”